imatinib mesylate has been researched along with Bone Diseases, Metabolic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akagi, T; Hiramatsu Asano, S; Iseki, M; Ishihara, K; Kittaka, M; Morita, Y; Mukai, T; Ono, M; Oohashi, T; Tosa, I; Ueki, Y; Yahagi, A | 1 |
| Iwaniec, UT; Marley, K; Sibonga, JD; Turner, RT | 1 |
2 other study(ies) available for imatinib mesylate and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Imatinib has minimal effects on inflammatory and osteopenic phenotypes in a murine cherubism model.
Topics: Adaptor Proteins, Signal Transducing; Animals; Bone Diseases, Metabolic; Cherubism; Imatinib Mesylate; Inflammation; Mice; Phenotype; Tumor Necrosis Factor-alpha | 2023 |
The role of mast cells in parathyroid bone disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Animals; Benzamides; Bone Diseases, Metabolic; Bone Marrow; Child; Child, Preschool; Female; Humans; Hyperparathyroidism; Imatinib Mesylate; Male; Mast Cells; Mice; Middle Aged; Osteitis Fibrosa Cystica; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Sprague-Dawley; Trapidil; Wortmannin | 2010 |